Lets take the New Zealand study as an example
Taken together, LMP formulation seems to increase bioavailability in humans by 26 to 40%, a level comparable to what we found in rodents (27% increase)
This appears to be positively correlated with changes in AVP binding to V1b receptors, reflecting changes in the number of binding sites and not their affinities
Other common symptoms include: Post-exertional malaise: Feeling worse after physical activity, often the next day Unrefreshing sleep: Waking up feeling unrefreshed, despite getting enough sleep Cognitive difficulties: Trouble concentrating and multi-tasking Orthostatic intolerance: Feeling lightheaded or experiencing a rapid heartbeat when standing up CFS/ME often involves cycles of flare-ups and remissions, with good days and bad days
Nat Rev Immunol (2003) 3:13346
doi: 10.3389/fgene.2026.1760654 Received 04 December 2025 Revised 29 December 2025 Accepted 05 January 2026 Published 20 January 2026 Volume 17 - 2026 Edited by Abhishek Kumar, Washington University in St
)
